Amphivena Therapeutics (subsidiary of Affimed AG), is developing a first-in-class bi-functional antibody therapy to address blood cancer indications with high unmet medical needs.
Amphivena Therapeutics, Inc
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/amphivena-therapeutics-inc-” connections=”true” suffix=””]
In 2013, Amphivena has entered into an agreement with Janssen Biotech, that grants Janssen the exclusive right, to acquire Amphivena going forward following IND approvals. As per terms, Janssen will provide Amphivena with an initial upfront payment plus additional contingent payments based on reaching predetermined milestones in return for its rights under the agreement.
Affimed AG has entered into a license and development agreement with Amphivena to support the discovery and pre-clinical development of the novel TandAb based therapy.
In July 2013, Amphivena completed a $14 Mn Series A equity financing led by MPM Capital, with participation from Aeris Capital and Affimed AG.